Publications

Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Key Publication

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

Cancers

Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases.

25-06-2022

Breast cancer research : BCR

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

17-06-2022

Molecular & cellular oncology

Filling in the gaps in PARP inhibitor-induced synthetic lethality.

15-04-2022

STAR protocols

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids.

18-03-2022

Cancer research

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

01-02-2022

Cancer research

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

15-12-2021

Nature reviews. Clinical oncology

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

01-12-2021

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

Key Publication

Cancers

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

27-10-2021

Molecular cell

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

05-08-2021

Cancers

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.

18-07-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Nature genetics

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-05-2021

Science advances

SMARCAD1-mediated active replication fork stability maintains genome integrity.

01-05-2021

Molecular & cellular proteomics : MCP

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate.

06-04-2021

Cancers

Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

22-03-2021

Current opinion in genetics & development

The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.

01-02-2021

Nature genetics

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-01-2021

Key Publication

Annals of oncology : official journal of the European Society for Medical Oncology

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

01-12-2020

Nat. Commun: Nature Communications

Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

30-11-2020

Nat. Commun: Nature Communications

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

21-09-2020

Current biology : CB

How the COVID-19 pandemic highlights the necessity of animal research.

21-09-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

01-09-2020

Nat Commun.

Sex differences in oncogenic mutational processes

28-08-2020

Cell reports

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

25-08-2020

Oncotarget

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

28-04-2020

Cancer research

Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.

01-04-2020

Oncoimmunology

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

03-03-2020

The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020

Science translational medicine

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

19-02-2020

Nat: Nature

Pan-cancer analysis of whole genomes

05-02-2020

Genes & development

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

01-02-2020

Journal of mammary gland biology and neoplasia

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

01-12-2019

Journal of mammary gland biology and neoplasia

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

01-09-2019

Nature communications

Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.

23-08-2019

British journal of cancer

Ductal carcinoma in situ: to treat or not to treat, that is the question.

01-08-2019

Key Publication

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Key Publication

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Cancer discovery

PARP Inhibitor Efficacy Depends on CD8⁺ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

01-06-2019

Nature cell biology

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

01-04-2019

Key Publication

The EMBO journal

Long-term expanding human airway organoids for disease modeling.

15-02-2019

Cancer research

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

01-02-2019

Nature

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

01-02-2019

Nature communications

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

23-01-2019

Nature communications

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.

17-12-2018

EMBO molecular medicine

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

01-12-2018

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases.

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Filling in the gaps in PARP inhibitor-induced synthetic lethality.

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids.

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

SMARCAD1-mediated active replication fork stability maintains genome integrity.

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate.

Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

How the COVID-19 pandemic highlights the necessity of animal research.

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

Sex differences in oncogenic mutational processes

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Pan-cancer analysis of whole genomes

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.

Ductal carcinoma in situ: to treat or not to treat, that is the question.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Long-term expanding human airway organoids for disease modeling.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

This site uses cookies

PARP Inhibitor Efficacy Depends on CD8⁺ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.